MA41809A - Biotine pour le traitement de la sclérose latérale amyotrophique - Google Patents

Biotine pour le traitement de la sclérose latérale amyotrophique

Info

Publication number
MA41809A
MA41809A MA041809A MA41809A MA41809A MA 41809 A MA41809 A MA 41809A MA 041809 A MA041809 A MA 041809A MA 41809 A MA41809 A MA 41809A MA 41809 A MA41809 A MA 41809A
Authority
MA
Morocco
Prior art keywords
biotin
treatment
lateral sclerosis
amyotrophic lateral
nmo
Prior art date
Application number
MA041809A
Other languages
English (en)
Other versions
MA41809B1 (fr
Inventor
Frédéric Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of MA41809A publication Critical patent/MA41809A/fr
Publication of MA41809B1 publication Critical patent/MA41809B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Magnetic Ceramics (AREA)

Abstract

L'invention concerne l'utilisation de la biotine pour le traitement de la sclérose latérale amyotrophique, ainsi que pour les neuropathies périphériques démyélinisantes et la neuromyélite optique (nmo).
MA41809A 2015-03-26 2016-03-25 Biotine pour le traitement de la sclérose latérale amyotrophique MA41809B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (fr) 2015-03-26 2015-03-26 Biotin pour le traitement de la sclérose latérale amyotrophique
PCT/EP2016/056696 WO2016151132A1 (fr) 2015-03-26 2016-03-25 Biotine pour le traitement de la sclérose latérale amyotrophique

Publications (2)

Publication Number Publication Date
MA41809A true MA41809A (fr) 2018-01-30
MA41809B1 MA41809B1 (fr) 2019-12-31

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41809A MA41809B1 (fr) 2015-03-26 2016-03-25 Biotine pour le traitement de la sclérose latérale amyotrophique

Country Status (23)

Country Link
US (2) US10357480B2 (fr)
EP (2) EP3072513A1 (fr)
JP (1) JP6752874B2 (fr)
KR (1) KR20170131543A (fr)
CN (2) CN111973592A (fr)
AU (1) AU2016238759B2 (fr)
BR (1) BR112017020408A2 (fr)
CA (1) CA2980660A1 (fr)
CY (1) CY1122374T1 (fr)
DK (1) DK3273957T3 (fr)
EA (1) EA034394B1 (fr)
ES (1) ES2748354T3 (fr)
HR (1) HRP20191491T1 (fr)
HU (1) HUE046116T2 (fr)
IL (1) IL254619B (fr)
LT (1) LT3273957T (fr)
MA (1) MA41809B1 (fr)
ME (1) ME03567B (fr)
PL (1) PL3273957T3 (fr)
PT (1) PT3273957T (fr)
RS (1) RS59149B1 (fr)
SI (1) SI3273957T1 (fr)
WO (1) WO2016151132A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (fr) 2015-03-26 2016-09-28 Medday Biotin pour le traitement de la sclérose latérale amyotrophique
EP3275439A1 (fr) 2016-07-29 2018-01-31 Medday Pharmaceuticals Procédé de traitement de l'encéphalopathie hépatique
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
DK1575531T3 (da) 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
WO2011077239A2 (fr) 2009-12-23 2011-06-30 Lupin Limited Compositions pharmaceutiques d'ilopéridone à libération lente
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
CA2833785C (fr) * 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions et methodes de traitement de maladie de devic
BR112014000742A2 (pt) * 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
CA2910717C (fr) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotine pour son utilisation dans le traitement d'une adrenoleucodystrophie liee a l'x
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (fr) 2015-03-26 2016-09-28 Medday Biotin pour le traitement de la sclérose latérale amyotrophique

Also Published As

Publication number Publication date
HRP20191491T1 (hr) 2019-11-15
MA41809B1 (fr) 2019-12-31
WO2016151132A1 (fr) 2016-09-29
LT3273957T (lt) 2019-11-11
CN111973592A (zh) 2020-11-24
ME03567B (fr) 2020-07-20
AU2016238759B2 (en) 2020-08-06
SI3273957T1 (sl) 2019-11-29
PT3273957T (pt) 2019-09-18
KR20170131543A (ko) 2017-11-29
EP3273957A1 (fr) 2018-01-31
JP6752874B2 (ja) 2020-09-09
AU2016238759A1 (en) 2017-10-05
EP3273957B1 (fr) 2019-08-14
HUE046116T2 (hu) 2020-02-28
US20180125825A1 (en) 2018-05-10
US10357480B2 (en) 2019-07-23
RS59149B1 (sr) 2019-09-30
PL3273957T3 (pl) 2020-01-31
EP3072513A1 (fr) 2016-09-28
CN107405335A (zh) 2017-11-28
US20190314342A1 (en) 2019-10-17
DK3273957T3 (da) 2019-11-11
EA034394B1 (ru) 2020-02-04
CY1122374T1 (el) 2021-01-27
EA201792124A1 (ru) 2018-04-30
ES2748354T3 (es) 2020-03-16
IL254619B (en) 2020-03-31
CA2980660A1 (fr) 2016-09-29
JP2018512451A (ja) 2018-05-17
BR112017020408A2 (pt) 2018-06-05
NZ735528A (en) 2021-09-24
IL254619A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
MA41013A (fr) Compositions comprenant des souches bactériennes
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA44322A (fr) Compositions comprenant des souches bactériennes
MA43187B1 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA55218A (fr) Eskétamine pour le traitement de la dépression
MA41809B1 (fr) Biotine pour le traitement de la sclérose latérale amyotrophique
FR3019465B1 (fr) Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen
MA42419A (fr) Méthode de traitement de l'encéphalopathie hépatique
MA39355A1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
TN2016000111A1 (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose.
FR3036620B1 (fr) Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires